EDIT news

Latest 3 stories · newest Oct 8, 2026

EDIT

Editas Medicine receives approval for Phase 1/2 EDIT-401 trial, aiming for 2027 data

Editas Medicine received approval to initiate the Phase 1/2 Strive trial of EDIT-401 in Australia to treat hyperlipidemia, with plans to report initial safety data in Q1 2027.

EDIT

This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

News Sep 23, 2026 sentiment 0.00 Source: benzinga.com ↗

EDIT

Editas EDIT-401 achieves ~90% reductions in LDL-C, Lp(a), ApoB in primates

Editas Medicine presented preclinical data showing EDIT-401 achieved robust ~90% mean reductions in multiple atherogenic lipoproteins in non-human primates with a single dose. The company plans to submit a CTN by mid-2026 and achieve early human proof-of-concept data by end of 2026, advancing its le…

Regulatory May 26, 2026 sentiment +0.85 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same EDIT feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/EDIT/newsSTART FREE